Fabrazyme Patients Ask FDA To Retool Genzyme's Product Distribution Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
If the agency stops Genzyme from exporting its Fabry disease treatment Fabrazyme (agalsidase beta), there will be enough for U.S. patients, a citizen petition says.